TrialPath
Recruiting

A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872 · Hoffmann-La Roche
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants With Type 2 Diabetes Mellitus
About this study
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of tifeglipron for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Eligibility criteria
Inclusion Criteria: * Have a diagnosis of Type 2 diabetes mellitus (T2D) for at least 6 months before screening * Have an HbA1c ≥7% and ≤10.5% at screening * Management of T2D with diet and exercise alone or with either a stable dose of metformin or/and sodium-glucose cotransporter-2 (SGLT-2) inhibitors * Body mass index (BMI) ≥23.0 kg/m\^2 at screening * A stable body weight within 3 months prior to screening (maximum 5% self-reported body weight gain and/or loss) Exclusion Criteria: * Have Type 1 diabetes (T1D), history of ketosis or hyperosmolar state/coma, or any other types of diabetes except T2D * Have had 1 or more episodes of Level 3 hypoglycemia or has hypoglycemia unawareness within the 6 months prior to screening * History or presence of proliferative diabetic retinopathy, diabetic macular edema, or non-proliferative diabetic retinopathy that requires acute treatment * Evidence of clinically significant/active nephropathy or neuropathy (including resting tachycardia, orthostatic hypotension, and diabetic diarrhea) * Current treatment or treatment within 3 months of screening with any other anti-hyperglycemic medication except metformin or SGLT-2 inhibitors * Have obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin-4 receptor deficiency or Prader-Willi Syndrome) * Have a known, clinically significant gastric emptying abnormality * Have poorly controlled hypertension at screening, untreated renal artery stenosis, or evidence of labile blood pressure including symptomatic postural hypotension * Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/transient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure
Study design
Enrollment target: 330 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2025-08-19
Estimated completion: 2028-02-05
Last updated: 2026-11-12
Interventions
Drug: TifeglipronDrug: SemaglutideDrug: Placebo
Primary outcomes
  • • Tifeglipron vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30 (Baseline to Week 30)
Sponsor
Hoffmann-La Roche · industry
Contacts & investigators
ContactReference Study ID Number: BP45703 https://forpatients.roche.com/ No attachments to email below. · contact · global-roche-genentech-trials@gene.com · 888-662-6728 (U.S. Only)
ContactFastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry · contact
InvestigatorClinical Trials · study_director, Hoffmann-La Roche
All locations (51)
Arizona Liver Health - TucsonRecruiting
Tucson, Arizona, United States
Orange County Research CenterRecruiting
Lake Forest, California, United States
Prospective Research Innovations Inc.Recruiting
Rancho Cucamonga, California, United States
Encompass Clinical ResearchRecruiting
Spring Valley, California, United States
Chase Medical ResearchRecruiting
Waterbury, Connecticut, United States
Emerson Clinical Research InstituteRecruiting
Washington D.C., District of Columbia, United States
K2 Medical Research South Orlando, LLCActive Not Recruiting
Clermont, Florida, United States
Center for Diabetes, Obesity and Metabolism IncCompleted
Pembroke Pines, Florida, United States
Rophe Adult and Pediatric Medicine/SKYCRNGActive Not Recruiting
Union City, Georgia, United States
Accellacare of Duly Health and CareActive Not Recruiting
Oak Lawn, Illinois, United States
Mercury Street Medical Group, PLLCWithdrawn
Butte, Montana, United States
Neurobehavioral Research, Inc.Completed
Cedarhurst, New York, United States
Accellacare of Piedmont HealthcareRecruiting
Statesville, North Carolina, United States
Accellacare of Wilmington, LLCRecruiting
Wilmington, North Carolina, United States
NexGen ResearchActive Not Recruiting
Lima, Ohio, United States
Tristar Clinical InvestigationsRecruiting
Philadelphia, Pennsylvania, United States
Alliance for Multispecialty Research. LLCWithdrawn
Knoxville, Tennessee, United States
Clinical Research AssociatesCompleted
Nashville, Tennessee, United States
Texas Diabetes & Endocrinology, P.A.Completed
Austin, Texas, United States
Apex Mobile Clinical ResearchActive Not Recruiting
Bellaire, Texas, United States
Velocity Clinical ResearchCompleted
Dallas, Texas, United States
Velocity Clinical Research (Impact Research Institute)Withdrawn
Waco, Texas, United States
Chrysalis Clinical ResearchCompleted
St. George, Utah, United States
Manassas Clinical Research CenterRecruiting
Manassas, Virginia, United States
Obudai Egeszsegugyi Centrum Kft.Completed
Budapest, Hungary
Qualiclinic Kft.Withdrawn
Budapest, Hungary
NZOZ Osteo-Medic s.c. A. Racewicz, J.SupronikCompleted
Bialystok, Podlaskie Voivodeship, Poland
Centrum Badan Klinicznych PI-House sp. z o.o.Active Not Recruiting
Gdansk, Pomeranian Voivodeship, Poland
Centrum Medyczne INTERCOR Sp. z o.o.Active Not Recruiting
Bydgoszcz, Poland
Pro Familia Altera Sp z o.o.Active Not Recruiting
Katowice, Poland
ETG LublinCompleted
Lublin, Poland
Ekamed sp. z o.o.Completed
Lublin, Poland
NZOZ METABOLICA Osrodek Badan KlinicznychActive Not Recruiting
Tarnów, Poland
ETG WarszawaCompleted
Warsaw, Poland
Centrum Badan KlinicznychActive Not Recruiting
Wroclaw, Poland
ETG ZamoscActive Not Recruiting
Zamość, Poland
Universidad de Sevilla - Hospital Universitario Virgen MacarenaCompleted
Seville, Barcelona, Spain
Instituto De Investigacion Marques De Valdecilla (IDIVAL)Completed
Santander, Cantabria, Spain
Hospital Vithas Nisa SevillaActive Not Recruiting
Castilleja de la Cuesta, Granada, Spain
Hospital Universitario A CorunaActive Not Recruiting
A Coruña, LA Coruna, Spain
Complexo Hospitalario Universitario de Ferrol (CHUF)Completed
Ferrol, LA Coruna, Spain
Hospital Regional Universitario de MalagaActive Not Recruiting
Malaga, Madrid, Spain
Hospital Universitario Virgen de la VictoriaCompleted
Málaga, Malaga, Spain
Centro Medico TeknonActive Not Recruiting
Barcelona, Spain
Hospital Universitario Vall d'HebronActive Not Recruiting
Barcelona, Spain
Hospital Clinic de Barcelona (Hospital Clinic i Provincial)Active Not Recruiting
Barcelona, Spain
Hospital General Universitario Gregorio Maranon (HGUGM)Active Not Recruiting
Madrid, Spain
Hospital Universitario Fundación Jimenez DíazActive Not Recruiting
Madrid, Spain
Nuevas Tecnologias en Diabetes y EndocrinologiaActive Not Recruiting
Seville, Spain
Hospital Quironsalud Infanta LuisaActive Not Recruiting
Seville, Spain
Hospital Clinico Universitario de Valencia (Instituto de Investigacion Sanitaria INCLIVA)Withdrawn
Valencia, Spain